In June 2026, a joint team from Nagoya University and RIKEN in Japan announced an important research breakthrough: the team developed a new strategy for precise, light-based bacterial killing by exploiting pathogenic bacteria's own nutrient-uptake channels, capable of selectively eliminating Acinetobacter — a globally significant multidrug-resistant bacterium. This technique, described as a "Trojan horse" approach to photodynamic bacterial killing, could offer a new way to combat drug-resistant infections.
Research Highlights
Using bacteria's own nutrient channels to smuggle in photosensitive molecules: the research team designed photosensitive compounds disguised as nutrients, which drug-resistant bacteria actively absorb; once inside the bacteria, the photosensitive molecules are activated by light of a specific wavelength, producing a bactericidal effect.
Achieving selective bacterial killing: because different bacteria have different nutrient-uptake channels, this method can relatively precisely target specific pathogenic bacteria, reducing the side effects associated with conventional broad-spectrum antibiotics.
Significant effectiveness against a globally significant drug-resistant bacterium: Acinetobacter baumannii is classified by the World Health Organization as one of the most dangerous drug-resistant bacteria, often causing severe pneumonia and sepsis; in experiments, the new technique achieved highly effective light-based inactivation of this pathogen.
How the Technology Works
The research team designed photosensitive compounds to mimic the structure of bacterial nutrients; once drug-resistant bacteria actively absorb the compound, light activation generates reactive oxygen species that directly kill the bacteria from within, without affecting human cells or the body's normal microbiota. This is the first research approach to achieve selective photodynamic bacterial killing by exploiting bacteria's own nutrient-uptake system.
What This Means for Patients Seeking Treatment in Japan
Research findings from Nagoya University and RIKEN are often translated into clinical application relatively quickly. This technology holds potential significance for patients with severe infections — particularly those who are long-term hospitalized, immunocompromised, or have undergone organ transplantation — and may eventually find broader application in medical devices, wound care, and respiratory infections. MIZUHO PHARMA will continue tracking the clinical translation progress of this technology and can help plan a path to relevant treatment in Japan.